Click here to go back to the English version of the broadcast
Événement sur demande

Breaking News from ATS.18

Date de première diffusion :
le mercredi 13 juin 2018

Durée : 1:03:42 minutes

Mettant en vedette

Paul O’Byrne, MB, FRCP(C), FRSC (Program Chair)
Shannon Walker, M.D., FRCPC
Paolo Renzi, M.D., FCCP, FRCPC
Alan Kaplan, M.D., CCFP(EM), FCFP

Membres du comité de planification scientifique

Paul O’Byrne M.B., FRCPC, FRSC (Président du programme)
Ronald Olivenstein, M.D.
Alan Kaplan, MD, CCFP(EM), FCFP
Paolo Renzi, M.D., FCCP, FRCPC
Shannon Walker, M.D., FRCPC


Obtenez les informations les plus récentes sur les données tirées d’essais présentés au congrès international 2018 de l’American Thoracic Society (ATS) à San Diego, CA!

Langue : Français et anglais

Questions and Answers

Q&A Section title: Asthma Clinical Studies Update (0:00:00)

  • Do you feel there are certain asthma populations that would benefit to one strategy compared to the other? And how would you manage that in your practice? (0:00:02)
  • In SYGMA 2, adherence was quite high at 63%. In real life, if we did not have that amount of adherence with maintenance therapy, might we have seen more benefit of the “as-needed” anti-inflammatory reliever therapy? (0:01:10)
  • With the SYGMA results and other pragmatic studies coming up, do you anticipate a change in practice and guidelines? (0:02:10)
  • Why did you use well-controlled asthma weeks as your primary outcome? (0:03:18)
  • What would be the outcome on airway remodeling? (0:04:14)

Q&A Section title: ATS Highlight Session: Reports of Recently Published Pulmonary Research (0:04:56)

  • The adherence rate was very high with these children. Could that high adherence rate of maintenance therapy, even at low dose, have been of significance for these patients entering yellow zone? (0:05:00)
  • How does the magnitude of benefit of quadrupling or quintupling ICS dose compare to taking oral prednisone? Are we able to compare the safety of high dose inhaled corticosteroid versus short bursts of oral prednisone? (0:05:52)
  • Was there any impact on pneumonia? (0:07:03)
  • What do you think your patients in general practice are most concerned about when it comes to inhaled corticosteroids? (0:07:39)
  • How should we incorporate the results of these studies for the children and adults in our clinical practice, and what impact might these have on our national guidelines? (0:08:19)

Q&A Section title: What Else was Hot at ATS? (0:09:30)

  • Do you not fear that the message sent to clinicians and patients through these studies may lead to a shift in the regular treatment to treatments “as necessary" that may harm the overall management of asthma? (0:09:34)
  • Is there a role for use of SABA alone in patients with very mild asthma, or exercise-induced asthma given that the rat study might show increased remodeling? Or should we be using medications like Symbicort instead for their pre-exercise or prn for very mild asthma? (0:10:40)
  • For children that were in the quadrupling ICS that did show a delayed growth, is there any data that demonstrates children DO catch up because their asthma is being treated? (0:13:00)
  • If we are adding tiotropium or a LAMA to our ICS/LABA maintenance, is there a risk that patients may only take the LAMA and not the ICS? (0:14:01)
  • What is the current recommendation for exercise-induced asthma: Symbicort, a SABA or Ventolin? (0:15:02)

Accréditation

L’activité Breaking News from ATS.18 répond aux critères de la section 2 (Vidéo) et est admissible à des crédits de la section 2 du programme de Maintien du certificat (MDC).

Watch the Bonus Q&A Session (16 min)